cropped-user_picto22.png
Biostatisticienne

2014                HDR (Ability to conduct scientific research), INSERM U897, Bordeaux University, France.
2010                Post-doctoral Fellow, INSERM U897, Bordeaux
2006               PhD, McGill University, Canada.
2001                MSc, McGill University, Canada.

Main

2009 –             Associate Research Fellow, INSERM U1219, Team EPICENE
2008 –             Biostatistician, INSERM CIC 14.01 (Clinical Research Centre – Clinical Epidemiology Unit)
2006 –             Biostatistician, Clinical Research & Clinical Epidemiology Unit, Institut Bergonié, Comprehensive Cancer Centre

 

Other: Collaborations & expertise

2014 –             Scientific collaborator, National Geriatric Oncology Platform “PACAN – Elderly and Cancer” of French League Against Cancer (LNCC).                   
2014 –             Scientific expert, Evaluation Committee of the French League Against Cancer (Ligue Régionale Contre le Cancer, Comité Paris-Ile-de-France,)
2014 –             Scientific collaborator, EUCLID, EUropean CLInical Trials Services, Platform & Development.
2013 –             Scientific collaborator, SIRIC-BRIO (Integrated Research in Oncology, Bordeaux), Epidemiology Program.
2011 –             Reference biostatistician, Urology group, UNICANCER, National Group of Comprehensive Cancer Centers
2010 – 2011   Reference biostatistician, Head and Neck group, UNICANCER, National Group of Comprehensive Cancer Centers.
2007 –             Reviewer & Expert, French National Cancer Institute (INCa)
2006 –            Supervisor, Master’s students and PhD student, INSERM, Epidemiology & Biostatistics.

  1. Bellera C, Proust-Lima C, Joseph L, Richaud P, Taylor J, Sandler H, Hanley J, Mathoulin-Pélissier S. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication. Stat Methods Med Res. 2016 [Epub ahead of print]
  2. Toulmonde M, Le Cesne A, Piperno-Neumann S, Penel N, Chevreau C, Duffaud F, Bellera C, Italiano A. Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. Ann Oncol. 2015 Jul;26(7):1465-70.
  3. Petit-Monéger A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pélissier S. Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. J Geriatr Oncol. 2016 Mar;7(2):99-107.
  4. Bellera C, Soubeyran P. [How to identify frailty in older patients with cancer? Available tools]. [Article in French]. Cancer Radiother. 2015 Oct;19(6-7):382-5.
  5. Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson, Durrieu J, Germain C, Mathoulin-Pélissier S, Soubeyran P, Rainfray M, Fonck M, Doussau A. One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic Score. PLoS One. 2016 Feb 9;11(2).
  6. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A’Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dallago L, Dalenc F, de Azambuja E, Debled M, Delaloge S, Filleron T, GlioGorov J, Gitowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Ida N, Offersen B, Penault-Llorca F, Pruneri G, Roché H, Russell N, Schmitt F, Servent V, Thuerlimann B, Untch M, Van der Hage J, Van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Annals Oncol 2015 (IF : 6.578, SIGAPS : A)
  7. Houédé N, Leutenegger E, Lomma M, Bellera C.Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study. PLoS One. 2015
  8. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2014 (IF : 6.578, SIGAPS : A).
  9. Mathoulin-Pélissier S, Chevreau C, Bellera C, Bauvin E, Savès M, Grosclaude P, Albert S, Goddard J, Le Guellec S, Delannes M, Bui BN, Mendiboure J, Stoeckle E, Coindre JM, Kantor G, Kind M, Cowppli-Bony A, Hoppe S, Italiano A. Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study.  Ann Oncol. 2014 ; 25(1):225-31 (IF : 6.578, SIGAPS : A).
  10. Sene M, Bellera C, Proust-Lima C. Shared random-effect models for the joint analysis of longitudinal and time-to-event data: application to the prediction of prostate cancer recurrence. Journal de la Société Française de Statistique 2014; 155(1): 134-155.
  11. Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G, Servent V, St Jean O, Van Pragh I, Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pélissier S, Rainfray M. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. Plos One 2014.
  12. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pesseau P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer (IF : 4.819, SIGAPS : B).
  13. Italiano A, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, Delcambre C, Penel N, Terrier P, Ranchere-Vince D, Lae M, Le Guellec S, Michels JJ, Robin YM, Bellera C, Bonvalot S. Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. Cancer 2014.
  14. Toulmonde M, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, Delcambre C, Penel N, Terrier P, Ranchère-Vince D, Lae M, Le Guellec S, Michels JJ, Robin YM, Bellera C, Italiano A. Long-term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow-up. Cancer 2014; 120(19):3003-6.
  15. Houédé N, Pulido M, Mourey L, Joly F, Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin MC, Ichas F, Puech A, Piazza PV. A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer. The Oncologist 2014 (IF : 4.54, SIGAPS : B)
  16. Bellera CA, Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo S, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials.  Eur J Cancer 2013 ; 49 : 769-81 (IF : 4.819, SIGAPS : B).
  17. Bellera C, Praud D, Petit-Monéger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-Pélissier S. Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin’s lymphoma: a systematic review.  Cancer Treat Rev 2013 Nov;39(7):812-7 (IF : 6.466, SIGAPS : A).
  18. Mathoulin-Pélissier S, Bellera C, Rainfray M, Soubeyran P. Screening methods for geriatric frailty. Lancet Oncol 2013 ; 14 : e1-e2 (IF : 24.725, SIGAPS : A).
  19. Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, Cassier P, Domont J, Takebe N, Kind M, Coindre JM, Blay JY, Bui B. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 ; 24(11):2922-6 (IF : 6.578, SIGAPS : A).
  20. Bullier E, Descat E, Bonichon F, Picat MQ, Bellera C, Evrard S, Cazeau AL. Diagnostic accuracy of 18F-FDG PET/CT for the detection of peritoneal carcinomatosis of colorectal origins. J Cancer Res Ther 2013 ; 1 : 46-53 (IF : 0.949, SIGAPS : E).
  21. Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, Mertens C, Blanc-Bisson C, Imbert Y, Cany L, Vogt L, Dauba J, Houédé N, Bellera C, Floquet A, Fabry MN, Ravaud A, Chakiba C, Mathoulin-Pélissier S, Soubeyran P. Functional decline in older patients with cancer receiving first-line chemotherapy.. J Clin Oncol 2013 ; 31(31):3877-82 (IF : 17.879, SIGAPS : A).
  22. Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, Soubeyran P. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012 ; 23 : 2166-72 (IF : 6.578, SIGAPS : A).
  23. Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, Palis R, Andriamampionona F, Houédé N, Floquet A, Chomy F, Brouste V, Ravaud A, Bellera C, Rainfray M. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012 ; 30 : 1829-34 (IF : 17.879, SIGAPS : A).
  24. Evrard S, Rivoire M, Arnaud JP, Lermite E, Bellera C, Fonck M, Bécouarn Y, Lalet C, Pulido M, Mathoulin-Pélissier S. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg 2012 ; 99 : 558-65 (IF : 5.21, SIGAPS : A).
  25. Toulmonde M, Bellera C, Mathoulin-Pélissier S, Debled M, Bui BN, Italiano A. Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol 2011 ; 29 : 1204-9 (IF : 17.879, SIGAPS : A).
  26. Debled M, Bellera C, Donamaria C, Soubeyran P. Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence? Cancer Treat Rev 2011 ; 37 : 590-8 (IF : 6.466, SIGAPS : A).
  27. Lebeau M, Mathoulin-Pélissier S, Bellera C, Tunon de Lara C, Daban A, Lipinski F, Jaubert D, Ingrand P, Migeot V, for the REPERES Group. Breast cancer care compared with clinical Guidelines: an observational study in France. BMC Public Health 2011 ; 11 : 45 (IF : 2.321, SIGAPS : C).
  28. Jarry J, Faucheron JL, Moreno W, Bellera C, Evrard S. Delayed colo-anal anastomosis is an alternative to prophylactic diverting stoma after total mesorectal excision for middle and low rectal carcinomas. Eur J Surg Oncol 2011 ; 37 : 127-33 (IF : 2.892, SIGAPS : C).
  29. Fonck M, Brunet R, Bécouarn Y, Legoux JL, Dauba J, Cany L, Smith D, Auby D, Terrebonne E, Traissac L, Mertens C, Soubeyran P, Bellera C, Rainfray M, Mathoulin-Pélissier S. Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study. Clin Res Hepatol Gastroenterol 2011 ; 35 : 823-30 (IF : 1.983, SIGAPS : D).
  30. Bellera CA, MacGrogan G, Debled M, Tunon de Lara C, Brouste V, Mathoulin-Pélissier S. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 2010 ; 10 : 20 (IF : 2.168, SIGAPS : C).
  31. Bellera CA, Julien M, Hanley JA. Normal approximations to the distributions of the Wilcoxon statistics: accurate to what N? Graphical insights. J Stat Educ 2010 ; 18 : 1-16.
  32. Soubeyran P, Mertens C, Bellera C, Mathoulin-Pélissier S, Rainfray M. Management of unfit patients with unfavourable non-Hodgkin’s lymphomas. Cancer Treat Rev 2009; 35 : 528-32 (IF : 6.466, SIGAPS : A).
  33. Bellera CA, Hanley JA, Joseph L, Albertsen PC. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. Ann Epidemiol 2008 ; 18 : 270-82 (IF : 2.145, SIGAPS : C).
  34. Bellera CA, Hanley JA, Joseph L, Albertsen PC. Detecting trends in noisy data series: application to biomarker series. Am J Epidemiol 2008 ; 167 : 1130-9 (IF : 4.975, SIGAPS : A).
  35. Bellera CA, Hanley JA. A method is presented to plan the required sample size when estimating regression-based reference limits. J Clin Epidemiol 2007 ; 60 : 610-5. (IF : 5.478, SIGAPS : A).
  36. Bellera CA, Hanley JA, Joseph L, Albertsen PC. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer. Int J Radiat Oncol Biol Phys 2009 ; 75 : 1357-63 (IF : 4.176, SIGAPS : B).
  37. Bellera CA, Hanley JA, Joseph L, Albertsen PC. A charting tool for estimating the PSA doubling time in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):315-6 (IF : 4.176, SIGAPS : B).
  38. Boulet LP, Thivierge RL, Bellera CA, Dorval E, Collet JP. Physicians’ assessment of asthma control in low vs. high asthma-related morbidity regions. J Asthma 2004 ; 41:813-24. (IF : 1.828, SIGAPS : D).
  39. Hanley JA, Turner E, Bellera C, Teltsch D. How long did their hearts go on? A Titanic study. BMJ 2003 ; 20:1457-8 (IF : 16.378, SIGAPS : A).
logo_ISPED logo_Université-de-Bordeaux logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_ARS logo_Charles-Perrens logo_IFSTTAR logo_HONcode